Jalil Emilia Moreira, Wilson Erin, Monteiro Laylla, Varggas Thaylla, Moura Isabele, Torres Thiago S, Hoagland Brenda, Cardoso Sandra Wagner, Ismerio Moreira Ronaldo, Gonçalves Veloso Dos Santos Valdilea, Grinsztejn Beatriz
Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Center for Public Health Research, San Francisco, Department of Public Health, San Francisco, CA, United States.
JMIR Res Protoc. 2023 Feb 3;12:e44157. doi: 10.2196/44157.
The HIV epidemic continues to disproportionately burden marginalized populations despite the availability of effective preventive and therapeutic interventions. Transgender women are severely affected by HIV worldwide including in Brazil and other low- and middle-income countries, with evidence of increasing new infections among young people. There is an urgent need for youth-specific HIV prevention and care interventions for young transgender women in Brazil.
This study aims to (1) address stigma in the Brazilian public health system and (2) reduce barriers to HIV care and prevention with systems navigation among young transgender women aged 18-24 years in Rio de Janeiro, Brazil.
The Brilhar e Transcender (BeT) study is a status-neutral, peer-led, single-arm digital intervention study enrolling 150 young transgender women in Rio de Janeiro, Brazil. The intervention was pilot tested and refined using data from a formative phase. The BeT intervention takes place over 3 months, is delivered remotely via mobile phone and in person by peers, and comprises three components: (1) BeT sessions, (2) digital interactions, and (3) automated messages. Eligibility criteria include identifying as transgender women, being aged 18-24 years, speaking in Portuguese, and living in the Rio de Janeiro metropolitan area in Brazil. The primary outcomes are HIV incidence, pre-exposure prophylaxis uptake, linkage to HIV care, and viral suppression. Primary outcomes were assessed at baseline and quarterly for 12 months. Participants respond to interviewer-based surveys and receive tests for HIV and sexually transmitted infections.
The study has been approved by the Brazilian and the US local institutional review boards in accordance with all applicable regulations. Study recruitment began in February 2022 and was completed in early July 2022. Plans are to complete the follow-up assessment of study participants on July 2023, analyze the study data, and disseminate intervention results by December 2023.
Interventions to engage a new generation of transgender women in HIV prevention and care are needed to curb the epidemic. The BeT study will evaluate a digital peer-led intervention for young transgender women in Brazil, which builds on ways young people engage in systems and uses peer-led support to empower transgender youth in self-care and health promotion. A promising evaluation of the BeT intervention may lead to the availability of this rapidly scalable status-neutral HIV intervention that can be translated throughout Brazil and other low- and middle-income countries for young transgender women at high risk of or living with HIV.
ClinicalTrials.gov NCT05299645; https://clinicaltrials.gov/ct2/show/NCT05299645.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/44157.
尽管有有效的预防和治疗干预措施,但艾滋病毒疫情继续给边缘化人群带来不成比例的负担。在全球范围内,包括在巴西和其他低收入和中等收入国家,跨性别女性受到艾滋病毒的严重影响,有证据表明年轻人中的新感染病例在增加。巴西迫切需要针对年轻跨性别女性的特定艾滋病毒预防和护理干预措施。
本研究旨在(1)消除巴西公共卫生系统中的污名化现象,(2)通过为巴西里约热内卢18至24岁的年轻跨性别女性提供系统导航,减少艾滋病毒护理和预防的障碍。
“闪耀与超越”(BeT)研究是一项不区分身份状态、由同伴主导的单臂数字干预研究,在巴西里约热内卢招募150名年轻跨性别女性。该干预措施通过形成阶段的数据进行了试点测试和完善。BeT干预为期3个月,通过手机远程进行,并由同伴亲自实施,包括三个部分:(1)BeT课程,(2)数字互动,(3)自动消息。入选标准包括自我认同为跨性别女性、年龄在18至24岁之间、讲葡萄牙语以及居住在巴西里约热内卢大都市区。主要结果是艾滋病毒发病率、暴露前预防措施的采用情况、与艾滋病毒护理的联系以及病毒抑制。在基线和之后的12个月内每季度评估一次主要结果。参与者接受基于访谈者的调查,并接受艾滋病毒和性传播感染检测。
该研究已获得巴西和美国当地机构审查委员会的批准,符合所有适用规定。研究招募于2022年2月开始,2022年7月初完成。计划于2023年7月完成对研究参与者的随访评估,分析研究数据,并在2023年12月前公布干预结果。
需要采取干预措施,让新一代跨性别女性参与艾滋病毒预防和护理,以遏制疫情。BeT研究将评估一项针对巴西年轻跨性别女性的由同伴主导的数字干预措施,该措施基于年轻人参与系统的方式,并利用同伴主导的支持来增强跨性别青年的自我护理和健康促进能力。对BeT干预措施进行的有前景的评估可能会促成这种可快速扩展的、不区分身份状态的艾滋病毒干预措施的推广,该措施可在巴西及其他低收入和中等收入国家推广,用于面临艾滋病毒感染高风险或已感染艾滋病毒的年轻跨性别女性。
ClinicalTrials.gov NCT0